IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience
Br J Haematol
.
2023 Nov;203(3):e87-e92.
doi: 10.1111/bjh.19027.
Epub 2023 Aug 3.
Authors
Naseema Gangat
1
,
Helen Ajufo
2
,
Maymona Abdelmagid
1
,
Omer Karrar
1
,
Kristen McCullough
1
,
Talha Badar
3
,
James Foran
3
,
Jeanne Palmer
4
,
Hassan Alkhateeb
1
,
Abhishek Mangaonkar
1
,
Andrew Kuykendall
5
,
Raajit K Rampal
2
,
Ayalew Tefferi
1
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
2
Leukemia Service, Department of Medicine, Memorial Sloan Kettering, New York, New York, USA.
3
Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
4
Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
5
Division of Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
PMID:
37537750
DOI:
10.1111/bjh.19027
No abstract available
Publication types
Letter